Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 29, 2023
Event: Entry into a Material Definitive Agreement for a registered direct offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 4,935,621 shares of Common Stock and warrants to purchase an equal number of shares (4,935,621).
- Offering Price: $4.66 per share of Common Stock plus accompanying Warrant.
- Gross Proceeds: Approximately $23 million (before fees and expenses).
- Warrant Terms:
- Exercise Price: $5.70 per share.
- Initial Exercisability: Six months following issuance.
- Expiration: Seven years from issuance.
- Exercise Method: Cash, unless a cashless exercise is permitted due to lack of an effective registration statement.
- Use of Proceeds: Research and development, manufacturing, working capital, and general corporate purposes.
- Expected Closing: On or about October 3, 2023.
Material Changes and Strategic Impact
This filing represents a significant capital raise event rather than a periodic financial performance report. The transaction is expected to:
- Fund operations into 2025.
- Enable the company to reach the topline data read-out from the HOPE-3, pivotal Phase 3 trial for CAP-1002 in the treatment of Duchenne Muscular Dystrophy.
Note: This filing does not provide comparative revenue, profit, cash flow, or margin data versus prior periods.
Guidance, Outlook, and Risks
Management Commentary: The company explicitly states that net proceeds will support operations through 2025 and facilitate the completion of a critical Phase 3 trial milestone.
Risks and Contingencies:
- The closing of the offering is subject to the satisfaction of customary closing conditions.
- Warrant exercise is contingent on the availability of an effective registration statement for cashless exercise options.
- The Purchase Agreement contains customary representations, warranties, and covenants that are qualified by the full text of the agreement.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting placement agent fees (Cantor Fitzgerald & Co. and H.C. Wainwright & Co.) and offering expenses.
- Confirm the dilution impact of the 4,935,621 new shares and the potential future dilution from the 4,935,621 warrants.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.
- Monitor the timeline for the HOPE-3 Phase 3 trial data read-out to ensure proceeds are utilized as intended.